However, osimertinib, but not erlotinib, suppressed ERK phosphorylation accompanied with DR4 reduction and PARP cleavage in another H1975 EGFRm NSCLC cell line (containing T790M) and in PC-9/GR, a laboratory-derived gefitinib-resistant EGFRm NSCLC cell line due to T790M mutation (Figures 1E and F). The gene discussed is TNFRSF10A; the disease is non-small cell lung carcinoma.